Caris Life Sciences Advances Precision Oncology at WCLC
Irving, Texas, USA, September 2, 2026 Caris Life Sciences will present new research highlighting advances in precision oncology, molecular...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Irving, Texas, USA, September 2, 2026 Caris Life Sciences will present new research highlighting advances in precision oncology, molecular...
Hong Kong, September 1, 2026 Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), has announced...
Stockholm, Sweden, August 21, 2026 Implantica AG has announced a major U.S. regulatory milestone after the U.S. Food and...
NEW YORK, August 21, 2026 The U.S. Food and Drug Administration (FDA) has cleared C2N Diagnostics’ PrecivityAD2 blood test,...
LONDON, United Kingdom, July 15, 2026 New research presented at the Alzheimer’s Association International Conference (AAIC) 2026 has revealed...
OSAKA, Japan; CAMBRIDGE, Massachusetts; JAKARTA, Indonesia — July 13, 2026 Takeda has entered into a landmark collaboration with the...
FREMONT, California, July 13, 2026 Alamar Biosciences has partnered with leading U.S. research universities to launch a national-scale proteomics...
NEWTON, Mass., July 7, 2026 Acumen Pharmaceuticals announced that it will present three scientific studies at the Alzheimer’s Association...
VANCOUVER, Wash., June 11, 2026 CytoDyn Inc. announced that the first patient has been dosed in the Phase 2a...
Fremont, California, March 17, 2026 Alamar Biosciences, Inc. announced the launch of its NULISAseq™ Neuro 220 Panel, a next-generation...
